Safety and tolerability of Low-Dose Naltrexone therapy in children with moderate to severe Crohn's disease: a pilot study

J Clin Gastroenterol
01 April 2014
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586944/

Background
There is an unmet need for safe and effective medicines to treat children with Crohn’s disease. Recently, investigations have shown an association between endogenous opioid peptides and inflammatory cells.

Apparent efficacy and safety of low dose naltrexone in Australian patients with active Crohn's disease

J Gastroenterology and Hepatology
October 2013
https://onlinelibrary.wiley.com/doi/epdf/10.1111/jgh.12365_6

Open label and randomised controlled trial evidence indicates that low dose naltrexone (LDN), a strong opioid antagonist, has efficacy in reducing inflammatory activity in patients with Crohn’s disease. All evidence has come from one institution. 

P-015 YI Low-Dose Naltrexone Therapy Improves Active Ulcerative Colitis

Inflam Bowel Dis
01 December 2013
https://academic.oup.com/ibdjournal/search-results?page=1&q=Low-Dose%20Naltrexone%20Therapy%20Improves%20Active%20Ulcerative%20Colitis&fl_SiteID=6136&SearchSourceType=1&allJournals=1

Tu1365 Low Dose Naltrexone in the Treatment of Crohn's Disease: A Case Series

Gastroenterology
April 2015
http://www.gastrojournal.org/article/S0016-5085(15)32952-8/abstract

Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial

Dig Dis Sci
July 2011
https://pubmed.ncbi.nlm.nih.gov/21380937/ 

Low-dose naltrexone for treatment of duodenal Crohn's disease in a pediatric patient

Inflamm Bowel Dis
September 2010
https://academic.oup.com/ibdjournal/article/16/9/1457/4628412

Low-dose naltrexone therapy improves active Crohn's disease

Am J Gastroenterol
April 2007
https://pubmed.ncbi.nlm.nih.gov/17222320/

Objectives: Endogenous opioids and opioid antagonists have been shown to play a role in healing and repair of tissues. In an open-labeled pilot prospective trial, the safety and efficacy of low-dose naltrexone (LDN), an opioid antagonist, were tested in patients with active Crohn's disease.

Psychoneuroimmunological approach to gastrointestinal related pain

Scand J Pain
October 2017
https://pubmed.ncbi.nlm.nih.gov/29122501/

The Use of Naltrexone in Low Doses Beyond the Approved Indication [Internet]

Report from Norwegian Knowledge Centre for the Health Services
April 2015
https://pubmed.ncbi.nlm.nih.gov/28510411/

The Safety and Efficacy of Low-Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn's Disease, and Other Chronic Pain Disorders

Pharmacotherapy
March 2018
https://pubmed.ncbi.nlm.nih.gov/29377216/